<?xml version="1.0"?>
<rss version="2.0">
	<channel>
		<title>All news.</title>
		<link>http://www.lifescience-online.com/</link>
		<description>News Feed Powered by Lifescience-online.com</description>
		<language>en-us</language>
		<pubDate>Wed, 07 Jan 2009 12:54:38 +0100</pubDate>
		<lastBuildDate>Wed, 07 Jan 2009 12:54:38 +0100</lastBuildDate>
		<category>News</category>		

		<image>
			<title>Lifescience-online</title>
			<url>http://rss.lifescience-online.com/images/logo.gif</url>
			<link>http://www.lifescience-online.com/</link>
			<width></width>
			<height></height>
			<description>Lifescience-online</description>
		</image>

		<item>
			<title>Strong growth in 2008 for OM PHARMA, the Swiss-based international bio-pharma group</title>
			<link>http://www.lifescience-online.com/Strong_growth_in_2008_for_OM_PHARMA__the_Swiss_bas,13637.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/6/3.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Finance and Income</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/om_pharma,4811.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>OM PHARMA</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/BRONCHO-VAXOM,20175.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>BRONCHO-VAXOM</u></font></a><br /><a href='http://www.lifescience-online.com/URO-VAXOM,20181.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>URO-VAXOM</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Wed, 07 Jan 2009 09:49:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis</title>
			<link>http://www.lifescience-online.com/DOR_BioPharma_Obtains_Fast_Track_Designation_for_D,13631.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/dor_biopharma,5548.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>DOR BIOPHARMA INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TIME-RELEASE_ORAL_BECLOMETHASONE_DIPROPIONATE,24367.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TIME-RELEASE ORAL BECLOMETHASONE DIPROPIONATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Tue, 06 Jan 2009 12:09:45 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>FORMA Therapeutics Debuts with 25 Million in Funding - Will Focus on Difficult Cancer Targets</title>
			<link>http://www.lifescience-online.com/FORMA_Therapeutics_Debuts_with_25_Million_in_Fundi,13638.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/6/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Finance and Income</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/forma_therapeutics,11096.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>FORMA Therapeutics Inc</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Vasogen (VSGN) Provides Corporate Update; Explores Sale of Company, Merger or Acquisition</title>
			<link>http://www.lifescience-online.com/Vasogen__VSGN__Provides_Corporate_Update__Explores,13639.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/1/1.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Industry and Sector</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/vasogen,1215.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>VASOGEN INC</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Advaxis, Inc. Phase II Clinical Trial HOLD Lifted</title>
			<link>http://www.lifescience-online.com/Advaxis__Inc__Phase_II_Clinical_Trial_HOLD_Lifted,13640.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/advaxis,4888.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Advaxis Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/LOVAXIN_C,20354.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>LOVAXIN C</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>DOR BioPharma Receives SPA Clearance From the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD</title>
			<link>http://www.lifescience-online.com/DOR_BioPharma_Receives_SPA_Clearance_From_the_FDA_,13610.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Immunomodulation</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/dor_biopharma,5548.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>DOR BIOPHARMA INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/ORAL_BECLOMETHASONE_DIPROPIONATE,2257.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>ORAL BECLOMETHASONE DIPROPIONATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 13:52:29 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9</title>
			<link>http://www.lifescience-online.com/Idera_Pharmaceuticals_Announces_Publication_of_Stu,13609.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/idera_pharmaceuticals,5827.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Idera Pharmaceuticals Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TLR-7,8,9_AGONISTS,22903.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TLR-7,8,9 AGONISTS</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 13:41:49 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>BioDelivery Sciences Closes $6 Million Transaction with Meda</title>
			<link>http://www.lifescience-online.com/BioDelivery_Sciences_Closes__6_Million_Transaction,13608.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/biodelivery_sciences_international,379.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>BIODELIVERY SCIENCES INTERNATIONAL INC</u></font></a><br /><a href='http://www.lifescience-online.com/meda_ab,9528.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>MEDA AB</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TRANSMUCOSAL_(BEMA)_FENTANYL,24181.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TRANSMUCOSAL (BEMA) FENTANYL</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 12:12:53 GMT</pubDate>
			<category>News</category>
		</item>

	</channel>
</rss>